Scotch Plains, NJ, United States of America

Philip J Sherratt

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Philip J. Sherratt: Innovator in Cereblon Modifying Compounds

Introduction

Philip J. Sherratt, based in Scotch Plains, NJ, is a notable inventor recognized for his contributions in the field of medicinal chemistry. With a focus on therapeutic strategies involving cereblon modifying compounds, Sherratt's work aims to enhance treatment options for various diseases and disorders.

Latest Patents

Sherratt holds one patent that reflects his innovative approach: "Methods for screening cereblon modifying compounds." This patent describes a method for determining the effectiveness of a cereblon modifying compound in treating a disease. The process involves obtaining a sample, evaluating the levels of a specific protein known as SALL, and assessing whether the compound induces degradation of this protein. This method is pivotal in selecting viable cereblon modifying compounds that do not compromise SALL levels, contributing to better therapeutic outcomes.

Career Highlights

Philip J. Sherratt has built a career marked by significant contributions in his field. He is currently affiliated with Celgene Corporation, a biopharmaceutical company known for its innovative approaches to drug development. His work with the company demonstrates a commitment to advancing scientific understanding and therapeutic possibilities in medicine.

Collaborations

Throughout his career, Sherratt has collaborated with distinguished colleagues, including Mary Matyskiela and Philip Chamberlain. These partnerships underline the collaborative nature of research and innovation in the scientific community, which often leads to groundbreaking developments.

Conclusion

Philip J. Sherratt's work exemplifies dedication to innovation in the pharmaceutical industry. His patent on screening cereblon modifying compounds is a testament to his commitment to enhancing therapeutic strategies for treating diseases. As he continues his work at Celgene Corporation, Sherratt remains a pivotal figure in the pursuit of effective medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…